2020

30.04.2020 – Cassiopea S.p.A.

Cassiopea announces results of ordinary shareholders meeting

Cassiopea announces results of ordinary shareholders meeting

Lainate – April 30, 2020 - Cassiopea SpA (SIX: SKIN), a clinical stage specialty pharmaceutical company focused on developing innovative and differentiated medical dermatology products, today announced the results of the shareholders meeting held on April 29, 2020 in Lainate.

Owing to the COVID-19 health emergency and in compliance with art. 106 of Law-Decree n. 18 dated March 17, 2020 aimed at minimizing travel and gatherings, attending and voting at the shareholders meeting could only occur through the granting of a specific proxy to the designated representative (Dario Trevisan, lawyer).

5,545,598 shareholder votes were represented at the shareholders meeting. This represents 55.45% of all votes.

The financial statements and the inherent and consequent resolutions were approved unanimously at the ordinary shareholders meeting.

5,490,472 votes representing 99% of the total votes cast, elected Jan de Vries as Chairman (non-executive) and non-executive board members Oyvind Bjordal, Pierpaolo Guzzo, Maurizio Baldassarini as well as CEO Diana Harbort as members of the board for one year until the next ordinary shareholders meeting.

5,490,472 votes representing 99% of the total votes cast approved the total board compensation of € 205,500.

The extraordinary shareholders meeting to decide on the proposed capital increase and on the employee stock options program will take place on May 28, 2020 in Lainate.

About Cassiopea

Cassiopea is a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action to address long-standing and essential dermatological conditions, particularly acne, androgenetic alopecia and genital warts. Cassiopea is investing in innovation that is driving scientific advancement in areas that have been largely ignored for decades. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. If approved, Cassiopea plans to commercialize the products directly in the USA and partner the products for countries outside of the USA. For further information on Cassiopea, please visit www.cassiopea.com.

Next events

Extraordinary Shareholders Meeting – 28 May 2020, Lainate

Jefferies Global Health Care Conference – 2-4 June 2020, New York

Half Year Report 2020 – July 2020

Investora – 23-24 September 2020, Zurich

Credit Suisse Small & Mid Cap Conference – 18-20 November 2020, Zurich

Contact:

Dr. Chris Tanner, CFO and Head of Investor Relations

Tel: +39 02 868 91 124

Some of the information contained in this press release may contain forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cassiopea has no obligation to publicly update or revise any forward-looking statements.


close